TransCode Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from TransCode Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 5,393,829% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than almost all Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $14 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 98% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 98% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-795.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 98% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
+61%Cash, after subtracting all debt, equals 61% of its market value (net cash).
Higher than 81% of Healthcare companies in United States.
Tangible Assets Ratio
14%Of every $100 the company owns, $14 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 98% of Healthcare companies in United States.
Tangible Net Worth Ratio
8%Of every $100 of net worth, $8 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 70% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
TransCode Therapeutics, Inc. made a loss over the last year. TransCode Therapeutics, Inc. owes $0.08 for every $1 it owns. TransCode Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossTransCode Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.21The share price is 0.21 times TransCode Therapeutics, Inc.'s book value per share, lower than 98% of Healthcare companies in United States.
Market cap
$29 MThe total market value of all of TransCode Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 80% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$138 MWhat TransCode Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$8.17Net worth divided by the number of shares. The share price of $1.72 is 0.2 times this, which is the P/B above.
Return on equity (ROE)
-59.3%TransCode Therapeutics, Inc. lost 59.3% of its shareholders' money over the last year, lower than 57% of Healthcare companies in United States.
Owes vs Owns
0.08×TransCode Therapeutics, Inc. owes $0.08 for every $1 it owns (low), lower than 90% of Healthcare companies in United States.
Dividend yield
NoneTransCode Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossTransCode Therapeutics, Inc. made a loss in each of the last two years.
Interest cover
Not coveredTransCode Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashTransCode Therapeutics, Inc. held $18 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For TransCode Therapeutics, Inc.: $29 M ÷ $138 M (30 Jun 2026) = 0.2.
What is TransCode Therapeutics, Inc.'s return on equity?
TransCode Therapeutics, Inc. lost 59.3% of its shareholders' money over the last year, lower than 57% of Healthcare companies in United States.
How much does TransCode Therapeutics, Inc. owe compared with what it owns?
TransCode Therapeutics, Inc. owes $0.08 for every $1 it owns (low), lower than 90% of Healthcare companies in United States.
Does TransCode Therapeutics, Inc. pay a dividend?
No. TransCode Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.